MIRA Pharmaceuticals, Inc. (MIRA) 股票分析

公司概述

MIRA Pharmaceuticals, Inc. operates as a pre-clinical-stage pharmaceutical development entity focused on advancing two neuroscience programs designed to address a spectrum of neurologic and neuropsychiatric disorders. The company holds exclusive rights in the United States, Canada, and Mexico for Ketamir-2, which represents a patent-pending oral formulation of ketamine. This business model places MIRA within the Healthcare sector, specifically the Drug Manufacturers - General industry, indicating a focus on the research and development of therapeutic agents rather than the distribution of generic or branded drugs. The company currently possesses a market capitalization of $42.86M, while annual revenue and employee count figures are not available in the current reporting cycle. These valuation metrics suggest that the firm is a small-cap entity with limited historical financial data, reflecting a typical profile for companies at the pre-clinical stage where capital allocation is directed primarily toward research and development activities rather than revenue generation.

财务健康

MIRA Pharmaceuticals reports a Net Income of $-31,999,306 over the trailing twelve-month period, whereas Revenue and EBITDA figures are not available for direct comparison in the current dataset. The substantial negative net income relative to the absence of reported revenue highlights a cost structure dominated by high upfront research and development expenses typical of pre-clinical-stage biotechnology firms. Free Cash Flow stands at $-812,591, indicating that the company is burning cash to fund its operations and development pipeline, which limits immediate financial flexibility but is a necessary condition for bringing neuroscience programs to market. All three margin metrics—Gross Margin, Operating Margin, and Profit Margin—are recorded at 0.0%, a figure that signifies the company has not yet achieved commercial sales or profitability from its product portfolio. On the balance sheet, the company holds $11.03M in cash against $572,865 in debt, resulting in a Debt to Equity ratio of 5.51. Despite the high debt-to-equity ratio, the liquidity position is supported by significant cash reserves relative to obligations, suggesting a leveraged yet cash-rich stance common in early-stage development. The Current Ratio is 15.75, which indicates an exceptionally strong ability to meet short-term liabilities with current assets, providing a robust buffer against immediate liquidity pressures. Return on Equity is -165.9% and Return on Assets is -93.6%, metrics that reveal the company is currently diluting shareholder value and utilizing assets to generate losses rather than returns, a characteristic expected for pre-revenue entities investing heavily in intellectual property.

估值评估

The Trailing P/E Ratio is not available due to negative earnings, while the Forward P/E is listed at -2.49. The negative forward multiple implies that the market anticipates continued negative earnings in the near term, consistent with the pre-clinical development status of the asset. The Price to Book ratio is 4.11, indicating that the market values the company at a significant premium over its net book value, a valuation multiple often driven by the potential value of intangible assets such as patent rights to Ketamir-2 rather than tangible assets. Price to Sales and EV/EBITDA are not available, precluding the use of these alternative metrics to gauge valuation relative to sales or operational efficiency. The stock has traded between a 52-Week High of $2.45 and a 52-Week Low of $0.78, reflecting a wide trading range that captures significant market sentiment volatility. The Beta value is 1.94, which indicates that the stock's price volatility is nearly double that of the broader market, exposing investors to elevated risk fluctuations compared to large-cap equities.

Growth & Income

Revenue Growth and Earnings Growth are not available in the current reporting cycle, preventing a direct comparison of earnings expansion relative to top-line growth rates. As a non-dividend payer, the company has a Dividend Yield of N/A and a Payout Ratio of 0.0%, confirming that all available earnings and cash flow are reinvested into research, development, and operational expansion rather than distributed to shareholders. The absence of dividend payments aligns with the company's strategic focus on funding the neuroscience programs and securing regulatory rights for Ketamir-2 in key markets. Overall, the growth and income profile is defined by a complete reinvestment strategy in the absence of commercial revenue streams, with no current income generation for shareholders.